The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

Highlights ► HPV vaccines have been universally approved for women up to 25 years. ► Women older than 16 years are not eligible for reimbursement in the Netherlands. ► We estimated the benefit and cost-effectiveness of vaccinating 17–25 year-old women. ► Refunding the cost of the vaccine is cost-eff...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-11, Vol.29 (48), p.8929-8936
Main Authors: Bogaards, Johannes A, Coupé, Veerle M.H, Meijer, Chris J.L.M, Berkhof, Johannes
Format: Article
Language:English
Subjects:
Adolescent
Adult
adults
Allergy and Immunology
Applied microbiology
Biological and medical sciences
carcinogenesis
Cervical cancer
Cost-Benefit Analysis
Cost-effectiveness
Cross Protection
Female
Fundamental and applied biological sciences. Psychology
girls
guidelines
Human papillomavirus
Human papillomavirus 16
Humans
Mass Vaccination
Medical sciences
Microbiology
Middle Aged
Miscellaneous
Models, Theoretical
Netherlands
Papillomaviridae
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - economics
prices
protective effect
quality-adjusted life year
Quality-Adjusted Life Years
risk
screening
Sensitivity and Specificity
Simulation model
simulation models
Tumors
uterine cervical neoplasms
Uterine Cervical Neoplasms - prevention & control
Vaccination
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
women
Womens health
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► HPV vaccines have been universally approved for women up to 25 years. ► Women older than 16 years are not eligible for reimbursement in the Netherlands. ► We estimated the benefit and cost-effectiveness of vaccinating 17–25 year-old women. ► Refunding the cost of the vaccine is cost-effective at a dose price of €65 or less. ► The clinical benefit moderately depends on cross-protection to non-vaccine types.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.09.055